|本期目录/Table of Contents|

[1]罗伟,吴静,方克伟.C-反应蛋白与前列腺癌相关性的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2020,22(5):516-520.[doi:10.3969/j.issn.1672-271X.2020.05.014]
　LUO Wei,WU Jing,FANG Ke-wei.Research progress on the relationship between C-reactive protein and prostate cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(5):516-520.[doi:10.3969/j.issn.1672-271X.2020.05.014]
点击复制

C-反应蛋白与前列腺癌相关性的研究进展()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第22卷
期数:
2020年5期
页码:
516-520
栏目:
综述
出版日期:
2020-09-09

文章信息/Info

Title:
Research progress on the relationship between C-reactive protein and prostate cancer
作者:
罗伟; 吴静; 方克伟
作者单位：650101昆明，昆明医科大学第二附属医院泌尿外科（罗伟、方克伟）；650500 昆明，昆明医科大学基础医学院生物化学与分子生物学系（吴静）
Author(s):
LUO Wei 1;  WU Jing2 ;  FANG Ke-wei 1
(1. Department of Urology, The 2nd Affiliated Hospital of Kunming Medical University, Kunming 650101, Yunnan, China; 2. Department of Biochemistry and Molecular Biology, Kunming Medical University, Kunming 650500, Yunnan, China)
关键词:
C-反应蛋白; 前列腺癌; 诊断; 预后
Keywords:
C-reactive protein;  prostate cancer;  diagnosis;  prognosis
分类号:
R737.35
DOI:
10.3969/j.issn.1672-271X.2020.05.014
文献标志码:
A
摘要:
近年来越来越多的研究关注炎症反应在肿瘤发生和发展中的作用，特别是亚临床的炎症反应，在许多研究中已经被证实在恶性肿瘤的发生和进展中起到了确定性的作用，也包括前列腺癌。C-反应蛋白（CRP）是临床中常用的炎症反应因子，具有易于测量的优势。目前，国内外对于CRP与前列腺癌的关系研究也主要集中于CRP在前列腺癌的发生、发展和预后判断中的作用。在众多的研究中，CRP不仅被证实对于前列腺癌的发生和发展起到了促进作用，且相关研究也指出这种促进作用可能是通过直接影响前列腺癌细胞或其所处的微环境而发生。虽然CRP对于前列腺癌的具体作用机制尚无明确定论，但是其与前列腺癌的相关性值得进一步讨论。文章主要对CRP在前列腺癌的发生、发展和预后判断中的作用进行综述。
Abstract:
Recent years, an increasing number of studies have paid attention to the role of inflammatory response in tumor occurrence and development, especially subclinical inflammatory response, which has been confirmed in many studies to play a definite role in the occurrence and progression of malignant tumors. Also includes prostate cancer. C-reactive protein (CRP) is a commonly used inflammatory response factor in clinical practice and has the advantage of being easy to measure. Presently, research on the relationship between CRP and prostate cancer at home and abroad mainly focuses on the role of CRP in the occurrence, development and prognosis of prostate cancer. In numerous studies, CRP has not only been proven to promote the occurrence and development of prostate cancer, but related studies have also pointed out that this promotion may occur by directly affecting prostate cancer cells or the microenvironment they are in. Although the specific mechanism of CRP for prostate cancer has not been definitively concluded, its relevance to prostate cancer is worthy of further discussion. This article mainly reviews the role of CRP in the occurrence, development and prognosis of prostate cancer.

参考文献/References:

[1]Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2]Eva-maria T, Krenn-pilko S, Langsenlehner U, et al. The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy[J]. Eur J Cancer, 2015, 51(5): 610-619.
[3]Xie DD, Chen YH, Xu S, et al. Low vitamin D status is associated with inflammation in patients with prostate cancer[J]. Oncotarget, 2017, 8(13):22076-22085.
[4]Elsberger B, Lankston L, Mcmillan DC, et al. Presence of tumoural C-reactive protein correlates with progressive prostate cancer[J]. Prostate Cancer Prostatic Dis, 2011, 14(2): 122-128.
[5]Grossman DC, Curry SJ, Owens DK, et al. Screening for prostate cancer: US preventive services task force recomm endation statement[J]. JAMA, 2018, 319(18):1901-1913.
[6]Hayashi T, Fujita K, Tanigawa G, et al. Serum monocyte fraction of white blood cells is increased in patients with high Gleason score prostate cancer[J]. Oncotarget, 2015, 8(21):35255-35261.
[7]Lee S, Choe JW, Kim HK, et al. High-sensitivity C-reactive protein and cancer[J]. J Epidemiol, 2011, 21(3):161-168.
[8]刘柯婷,周淑宇,蔡必扬,等.高敏C反应蛋白和大动脉粥样硬化型卒中严重程度的相关性研究[J].医学研究生学报,2015,28(10):1043-1047.
[9]徐杨,丛壮壮,冀赛光,等.C-反应蛋白与清蛋白比值对微创食管癌术后并发症的早期预测价值[J].东南国防医药,2018,20(4):371-375.
[10]周小林.CRP和Alb与初诊断的非小细胞肺癌临床病理特征联系及预后价值分析[J].东南国防医药,2016,18(5):489-492.
[11]Stikbakke E, Richardsen E, Knutsen T, et al. Inflammatory serum markers and risk and severity of prostate cancer: The proca-life study[J]. Int J Cancer, 2020, 147(1):84-92.
[12]Stark JR, Li H, Kraft P, et al. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality[J]. Randomized Controlled Trial, 2009, 124(11):2683-2689.
[13]Lehrer S, Diamond EJ, Mamkine B, et al. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer[J]. BJU Int, 2005, 95(7):961-962.
[14]García Rodríguez LA, González-Pérez A. Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer[J]. Cancer Epidemiol Biomarkers Prev, 2004, 13(4):649-653.
[15]Eklund CM, Tammela TLJ, Schleutker J, et al. C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk[J]. Br J Cancer, 2009, 100(12):1846-1851.
[16]Allin KH, Bojesen SE, Nordestgaard BG. Inflammatory biomarkers and risk of cancer in 84,000 individuals from the general population[J]. Int J Cancer,2016, 139(7):1493-1500.
[17]Demir S. Role of sterile pyuria in association to elevated PSA values in the diagnosis of non-palpable prostate cancer?[J] Arch Ital Urol Androl,2019 91(3):167.
[18]Tulloch-Reid MK, Mcfarlane-Anderson N, Bennett FI, et al. Effects of cholesterol, C-reactive protein, and interleukin-6 on prostate cancer risk in a population of African ancestry[J]. Cancer Causes Control, 2017, 28(11):1313-1321.
[19]Siemes C, Visser LE, Coebergh JWW, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the rotterdam study[J]. J Clin Oncol, 2006, 24(33):5216-5222.
[20]Jabs WJ, Busse M, Krüger S, et al. Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue[J]. Kidney Int, 2005, 68(5):2103-2110.
[21]Ito M, Saito K, Yasuda Y, et al. Prognostic impact of C-reactive rrotein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel[J]. Urology, 2011, 78(5):1131-1135.
[22]Dai J, Tang K, Xiao W, et al. Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis[J]. APJCP, 2014, 15(8):3369-3375.
[23]Danielle C, Robert W, Hans G,et al. Serum inflammatory markers in relation to prostate cancer severity and death[J]. Eur J Surg Oncol, 2018, 44（1）:S25.
[24]Rocha P, Charity JM, Templeton AJ, et al. Prognostic impact of C-reactive protein in metastatic prostate Cancer: a systematic review and Meta-Analysis[J]. Oncol Res Treat, 2014(37): 772-776.
[25]Mccall P, Catlow J, Mcardle PA, et al. Tumoral C-reactive protein and nuclear factor kappa-b expressionare associated with clinical outcome in patients with prostate cancer[J]. Cancer Bio, 2011, 10(2):91.
[26]Xu L, Zhao Q, Huang S, et al. Serum C-reactive protein acted as a prognostic biomarker for overall survival in metastatic prostate cancer patients[J]. Tumor Biol, 2015, 36(2):669-673.
[27]Liao SG, Cheng HH, Lei Y. C-Reactive protein is a prognostic marker for patients with castration-resistant prostate cancer[J]. Oncol Res Treat, 2016, 39(5):266-271.
[28]Beer TM, Lalani AS, Lee S, et al. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer : results from the ascent trial[J]. Cancer, 2008, 112(11):2377-2383.
[29]Xu Q, Chen YJ, Liu ZQ, et al. Prognostic role of C-reactive protein in prostate cancer: a systematic review and meta-analysis[J]. Asian J Androl, 2014, 16(3):467.
[30]Julie NG, Tomase MB, Blan L, et al. Pooled analysis of C-reactive protein levels and mortality in prostate Cancer patients[J]. Clin Genitour Cancer, 2015, 13(4): e22-e217 .
[31]Nakashima J, Kikuchi E, Miyajima A, et al. Simple stratification of survival using bone scan and serum C-reactive protein in prostate cancer patients with metastases[J]. Urol Int, 2008, 80(2):129-133.
[32]Helzlsouer K, Erlinger T, Platz E. Article history: received 11 january 2006 accepted 11 january 2006 available online 2 march 2006[J]. Eur J Cancer, 2006(42): 704-707.
[33]Liu Y, Chen JQ, Xie L, et al. Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis[J]. BMC Med, 2014, 12(1):55.
[34]Sevcenco S, Mathieu R, Baltzer P, et al. The prognostic role of preoperative serum C-reactive protein in predicting the biochemical recurrence in patients treated with radical prostatectomy.[J]. Prostate Cancer Prostatic Dis, 2016, 19(2): 163-167.
[35]Pinkawa M, Ribbing C, Djukic V, et al. Early hematologic changes during prostate cancer radiotherapy predictive for late urinary and bowel toxicity[J]. Strahlenther Onkol, 2015, 191(10): 771-777.
[36]Hall WA, Nickleach DC, Master VA, et al. The association between C-reactive protein (CRP) level and biochemical failure-free survival in patients after radiation therapy for nonmetastatic adenocarcinoma of the prostate[J]. Cancer, 2013, 119(18):3272-3279.
[37]Linton A, Pond G, Clarke S, et al. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy[J]. Clin Genitour Cancer, 2013, 11(4):423-430.
[38]Sciarra A, Gentilucci A, Salciccia S, et al. Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review[J]. J Inflamma, 2016, 13(1):35.

相似文献/References:

[1]翟金盛,王晓玲,王 颖.前列腺癌患者社会支持和抑郁状况调查及相关性分析[J].医学研究与战创伤救治(原医学研究生学报),2015,17(01):67.[doi:10.3969/j.issn.1672-271X.2015.01.022]
　ZHAI Jin-sheng,WANG Xiao-ling,WANG Ying..Social support， depression and their correlation in the prostate cancer patients[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(5):67.[doi:10.3969/j.issn.1672-271X.2015.01.022]
[2]段 松.前列腺癌组织中Skp2的表达及其与前列腺癌术后复发的关系[J].医学研究与战创伤救治(原医学研究生学报),2016,18(01):47.[doi:10.3969/j.issn.1672-271X.2016.01.014]
　DUAN Song..The expression of Skp2 in prostate cancer and its relationship with postoperative recurrence[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2016,18(5):47.[doi:10.3969/j.issn.1672-271X.2016.01.014]
[3]赵色玲,王凡,许春,等.血清降钙素原与C反应蛋白及内毒素在经皮肾镜取石术后尿脓毒症早期诊断中的价值[J].医学研究与战创伤救治(原医学研究生学报),2018,20(02):130.[doi:10.3969/j.issn.1672-271X.2018.02.005]
　ZHAO Se-ling,WANG Fan,XU Chun,et al.The significance of procalcitonin, C reactive protein and lipopolysaccharide in the early diagnosis of urinary sepsis after percutaneous nephrolithotomy[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2018,20(5):130.[doi:10.3969/j.issn.1672-271X.2018.02.005]
[4]高杰,丁留成,卫中庆.脂质代谢在去势抵抗性前列腺癌中的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2021,23(02):169.[doi:10.3969/j.issn.1672-271X.2021.02.013]
　GAO Jie,DING Liu-cheng,WEI Zhong-qing.Research progress of lipid metabolism in castration-resistant prostate cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(5):169.[doi:10.3969/j.issn.1672-271X.2021.02.013]
[5]黄明清,翁雨亭,方克伟.雌激素受体的生物学功能及其在骨骼肌发育和前列腺癌中作用的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2022,24(2):172.[doi:10.3969/j.issn.1672-271X.2022.02.013]
　HUANG Ming-qing,WENG Yu-ting,FANG Ke-wei.Advances in the study of the biological function of estrogen receptor and its role in skeletal muscle development and prostate cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(5):172.[doi:10.3969/j.issn.1672-271X.2022.02.013]

备注/Memo

备注/Memo:
基金项目：云南省卫生和计划生育委员会医学学科带头人培养项目（D-201615）；云南省科学和技术带头人后备人才培养项目（2017HB038）
更新日期/Last Update: 2020-09-09